This article, published in Human Vaccines, describes the projected effectiveness of RotaTeq®, which is an oral pentavalent rotavirus vaccine (RV5), against rotavirus gastroenteritis (RGE)-related hospitalizations and deaths in six Asian countries based on a simple mathematical model. The model projected an overall effectiveness in the region of 82 to 89 percent against RGE-related hospitalizations and a substantial reduction in RGE-related deaths, suggesting that RV5 could substantially reduce the burden of rotavirus disease in Asia.

Author(s): El Khoury AC, Mast TC, Ciarlet M, Markson LE, Goveia MG

Published: 2011

Resource types: Peer-reviewed journal

Diseases: Rotavirus

Topics: Disease burden and surveillance; Disease/vaccine specific information

Regions: Asia